TorreyPines Therapeutics Completes Second Phase I Study For NGX267, A Selective M1 Agonist For The Treatment Of Alzheimer's Disease

... TorreyPines Therapeutics, Inc. todayannounced completion of its second Phase I study with NGX267 in clinicaldevelopment for the treatment of Alzheimer's disease. This study evaluatedthe safety of NGX267 in healthy elderly volunteers. In a previous Phase Istudy, NGX267, administered as single doses, was shown to be well-toleratedin healthy, younger adult males. [click link for full article] ...